Free Trial

Biomerica Q2 2024 Earnings Report

Biomerica logo
$0.28 +0.01 (+4.85%)
(As of 12/20/2024 05:31 PM ET)

Biomerica EPS Results

Actual EPS
-$0.09
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biomerica Revenue Results

Actual Revenue
$1.57 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomerica Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Trump’s Sending THIS Crypto Higher on Purpose (Ad)

Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…

YES, I WANT THE #1 CRYPTO NOW

Biomerica Earnings Headlines

Biomerica secures three key international patents for inFoods Technology
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
Biomerica granted additional 180-day period to meet listing compliance
See More Biomerica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomerica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomerica and other key companies, straight to your email.

About Biomerica

Biomerica (NASDAQ:BMRA), a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

View Biomerica Profile

More Earnings Resources from MarketBeat

Upcoming Earnings